Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (36)
Valentina Pala, Simone Ribero, Pietro Quaglino & Luca Mastorino. (2023) Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics. Journal of Clinical Medicine 12:23, pages 7486.
Crossref
Crossref
Loris Riccardo Lopetuso, Claudia Cuomo, Irene Mignini, Antonio Gasbarrini & Alfredo Papa. (2023) Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases. International Journal of Molecular Sciences 24:9, pages 8187.
Crossref
Crossref
Achmad Himawan, Lalitkumar K. Vora, Andi Dian Permana, Sumarheni Sudir, Airin R. Nurdin, Ririn Nislawati, Rafikah Hasyim, Christopher J. Scott & Ryan F. Donnelly. (2022) Where Microneedle Meets Biomarkers: Futuristic Application for Diagnosing and Monitoring Localized External Organ Diseases. Advanced Healthcare Materials 12:5, pages 2202066.
Crossref
Crossref
Amir Mohammad Beyzaee, Mohamad Goldust, Anant Patil, Ghasem Rahmatpour Rokni & Samira Beyzaee. (2022) The role of cytokines and vitamin D in vitiligo pathogenesis. Journal of Cosmetic Dermatology 21:11, pages 6314-6325.
Crossref
Crossref
Liesbeth Delbaere, Reinhart Speeckaert, Sandrine Herbelet, Arno Belpaire, Jolien Duponselle & Nanja van Geel. (2022) Biomarkers and clinical indicators of disease activity in vitiligo. Dermatological Reviews 3:5, pages 289-307.
Crossref
Crossref
Xin Yu, Yuli Cui, Xueqing Zhu, Hongjun Xu, Linfeng Li & Guangcheng Gao. (2022) MicroRNAs: Emerging players in the pathogenesis of vitiligo. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Hediye Eker, Zeynep Gizem Kaya İslamoğlu & Abdullah Demirbaş. (2022) Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab. Dermatologic Therapy 35:4.
Crossref
Crossref
Paolo Custurone, Luca Di Bartolomeo, Natasha Irrera, Francesco Borgia, Domenica Altavilla, Alessandra Bitto, Giovanni Pallio, Francesco Squadrito & Mario Vaccaro. (2021) Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments. International Journal of Molecular Sciences 22:21, pages 11429.
Crossref
Crossref
Nada Jaouad, Kawther Ben Abdelghani, Meriem Sellami, Fadoua Khadiri, Bouchra Amine, Imane Elbinoune, Alia Fazaa, Ahmed Laatar & Rachid Bahiri. (2021) Vitiligo and anti-tumor necrosis factors: Cases report. Therapies 76:5, pages 504-507.
Crossref
Crossref
Kalai Selvi Rajendiran, Medha Rajappa, Laxmisha Chandrashekar, Devinder Mohan Thappa & Panneer Devaraju. (2020) Association Analysis of Tumor Necrosis Factor Alpha Promoter Polymorphisms and Vitiligo Susceptibility in South Indian Tamils. Dermatology 236:6, pages 554-564.
Crossref
Crossref
Ali Rahimi, Hadi Hossein‐Nataj, Zohreh Hajheydari, Zeinab Aryanian, Asghar Shayannia, Abolghasem Ajami & Hossein Asgarian‐Omran. (2019) Expression analysis of PD‐1 and Tim‐3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity. Experimental Dermatology 28:6, pages 674-681.
Crossref
Crossref
Xiya Lu, Yunlu Gao & Yangfeng Ding. (2019) Vitiligo in a patient receiving infliximab for chronic plaque psoriasis. Dermatologic Therapy 32:3.
Crossref
Crossref
Kirsten C. Webb, Steven W. Henning & I. Caroline Le Poole. 2019. Vitiligo. Vitiligo
285
301
.
Jung Min Bae, Miri Kim, Han Hee Lee, Ki-Jo Kim, Hyoseung Shin, Hyun Jeong Ju, Gyong Moon Kim, Chul Jong Park & Hyun Jeong Park. (2018) Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study. Journal of Investigative Dermatology 138:4, pages 768-774.
Crossref
Crossref
Vishal Gupta & Somesh Gupta. 2018. Vitiligo. Vitiligo
475
489
.
Pablo Michel & Amit G. Pandya. 2018. Vitiligo. Vitiligo
151
157
.
Grace W. Kimmel, John K. Nia, Peter W. Hashim & Mark G. Lebwohl. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
295
308
.
R. Speeckaert, M. Speeckaert, S. De Schepper & N. van Geel. (2017) Biomarkers of disease activity in vitiligo: A systematic review. Autoimmunity Reviews 16:9, pages 937-945.
Crossref
Crossref
Michelle Rodrigues, Khaled Ezzedine, Iltefat Hamzavi, Amit G. Pandya & John E. Harris. (2017) Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology 77:1, pages 17-29.
Crossref
Crossref
Stanca A. Birlea, Nathaniel B. Goldstein & David A. Norris. (2017) Repigmentation through Melanocyte Regeneration in Vitiligo. Dermatologic Clinics 35:2, pages 205-218.
Crossref
Crossref
L. Méry-Bossard, K. Bagny, G. Chaby, A. Khemis, F. Maccari, H. Marotte, J.L. Perrot, Z. Reguiai, M.L. Sigal, M. Avenel-Audran, T. Boyé, A. Grasland, J. Gillard, D. Jullien & E. Toussirot. (2017) New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. Journal of the European Academy of Dermatology and Venereology 31:1, pages 181-186.
Crossref
Crossref
Mario Vaccaro, Francesca Cicero, Carmen Mannucci, Gioacchino Calapai, Giovanna Spatari, Olga Barbuzza, Serafinella P. Cannav?Sebastiano Gangemi. (2016) IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Archives of Dermatological Research 308:7, pages 527-530.
Crossref
Crossref
Jun Zhou, Zhenyu Zhong, Jian Li & Wenwen Fu. (2016) Motor nerve conduction velocity is affected in segmental vitiligo lesional limbs. International Journal of Dermatology 55:6, pages 700-705.
Crossref
Crossref
E.H. Kemp. (2015) Tumour necrosis factor-α antagonists as therapies for vitiligo. British Journal of Dermatology 173:3, pages 635-635.
Crossref
Crossref
K.C. WebbR. TungL.S. WinterfieldA.B. GottliebJ.M. EbyS.W. HenningI.C. Le Poole. (2015) Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. British Journal of Dermatology 173:3, pages 641-650.
Crossref
Crossref
Mario Vaccaro, Serafinella P. Cannavò, Selene Imbesi, Mariateresa Cristani, Olga Barbuzza, Valeria Tigano & Sebastiano Gangemi. (2015) Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. International Journal of Dermatology 54:6, pages 672-674.
Crossref
Crossref
Yiping Zhu, Suiquan Wang, Fuquan Lin, Qing Li & Aie Xu. (2014) The therapeutic effects of EGCG on vitiligo. Fitoterapia 99, pages 243-251.
Crossref
Crossref
Amir Kalafi & Farideh Jowkar. (2014) Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. ISRN Dermatology 2014, pages 1-6.
Crossref
Crossref
Yu-Ling Shi, Matthew Weiland, Henry W. Lim, Qing-Sheng Mi & Li Zhou. (2014) Serum miRNA expression profiles change in autoimmune vitiligo in mice. Experimental Dermatology 23:2, pages 140-142.
Crossref
Crossref
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
473
494
.
É. Toussirot, D. Salard, M.-P. Algros & F. Aubin. (2013) Développement d’un vitiligo au cours du traitement d’une spondylarthrite ankylosante par adalimumab. Annales de Dermatologie et de Vénéréologie 140:12, pages 801-802.
Crossref
Crossref
G. W. Moran, A. W. K. Lim, J. L. Bailey, M.-F. Dubeau, Y. Leung, S. M. Devlin, K. Novak, G. G. Kaplan, M. Iacucci, C. Seow, L. Martin, R. Panaccione & S. Ghosh. (2013) Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 38:9, pages 1002-1024.
Crossref
Crossref
Carlos R. Camara-Lemarroy & Julio C. Salas-Alanis. (2013) The Role of Tumor Necrosis Factor-α in the Pathogenesis of Vitiligo. American Journal of Clinical Dermatology 14:5, pages 343-350.
Crossref
Crossref
H. Seif El Nasr, O.G. Shaker, M.M.T. Fawzi & G. El-Hanafi. (2013) Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. Journal of the European Academy of Dermatology and Venereology 27:1, pages 103-108.
Crossref
Crossref
Igor V. Korobko. (2012) Review of current clinical studies of vitiligo treatments. Dermatologic Therapy 25, pages S17-S27.
Crossref
Crossref
A. Miniati, Z. Weng, B. Zhang, A.J. Stratigos, E. Nicolaidou & T.C. Theoharides. (2012) Neuro-Immuno-Endocrine Processes in Vitiligo Pathogenesis. International Journal of Immunopathology and Pharmacology 25:1, pages 1-7.
Crossref
Crossref